References
- Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.
- Schuppan D, Afdhal NH. Liver cirrhosis. The Lancet. 2008;371:838–851.
- Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol. 2008;64:1147–61.
- Benet LZ, Hoener B. Changes in plasma protein binding have litlee clinical relevance. Clin Pharmacol Ther. 2002;71:115–121.
- Barre J, Houin G, Rosenbaum J, et al. Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol. 1984;18:652–653.
- Hayes PC, Plevris JN, Bouchier IA. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J Hum Hypertens. 1989;3(Suppl 1):153–158.
- Thiessen JJ, Sellers EM, Denbeigh P, et al. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol. 1976;16:345–351.
- Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther. 1974;15:276–282.
- Rowland M, Tozer TN. Disease. In: Clinical pharmacokinetics & pharmacodynamics: concepts and applications. Baltimore (MD): Lippincott Williams & Wilkins, Wolters Kluwer Business; 2011. p. 403–444.
- Larson AM, Drugs and the liver: metabolism and mechanisms of injury. In UpToDate. Post TW Ed, UpToDate;Waltham, MA. (Accessed on August 25 2015).
- Bass NM, Williams RL, Guide to drug dosage in hepatic disease. Clin Pharmacokinet. 1988;15:396–420.
- Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, et al. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 2012;104:165–84.
- Center for Drug Evaluation and Research, Food and Drug Administration. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. [Internet]. Rockville: 2003 [cited 2015 Aug 15]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf.
- CHMP, European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function [Internet]. London: 2005 [cited 2015 Aug 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf
- Brockmöller J, Roots I. Assessment of liver metabolic function. clinical implications. Clin Pharmacokinet. 1994;27:216–248.
- Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther. 2002;16:1977–1996.
- Burra P, Masier A. Dynamic tests to study liver function. Eur Rev Med Pharmacol Sci. 2004;8:19–21.
- Shimaoka S, Ohi R, Nio M, et al. Clinical significance of 99mTc-DTPA galactosyl human serum albumin scintigram in follow-up after Kasai operation. Tohoku J Exp Med. 1997;181:203–211.
- Setchell KD, Welsh MB, Klooster MJ, et al. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load. An indicator of liver function. J Chromatogr. 1987;385:267–274.
- Balistreri WF, A-Kader HH, Setchell KD, et al. New methods for assessing liver function in infants and children. Ann Clin Lab Sci. 1992;22:162–174.
- Burdelski M, Oellerich M, Düwel J, et al. Pre- and post-transplant assessment of liver function in paediatric liver transplantation. Eur J Pediatr. 1992;151(Suppl S1):SS39–43.
- Nakamura H, Tanaka E, Kaneko M, et al. The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia. J Clin Pharm Ther. 2001;26:417–424.
- Wiela-Hojenska A, Gorczynska E, Orzechowska-Juzwenko K, et al. Metabolic functions of the liver during chemotherapy in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2001;39:246–250.
- Sakka SG. Assessing liver function. Curr Opin Crit Care. 2007;13:207–214.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128.
- Wyles DL, Gerber JG, Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174–181.
- Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497.
- Lewis JH, Stine JG, Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132–1156.
- European Medicines Agency. Pegasys: EPAR - Product Information [Internet]. 2014 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf
- European Medicines Agency. Rebetol: EPAR - Product Information [Internet]. 2014 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf
- Glue P, Schenker S, Gupta S, et al. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol. 2000;49:417–421.
- European Medicines Agency. Victrelis: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf
- Food and Drug Administration. Victrelis: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2013 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf
- Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619–628.
- European Medicines Agency. Incivo: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf
- Food and Drug Administration. Incivek: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2011 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf.
- Garg V, Kauffman RS, Beaumont M, et al. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (Lond.). 2012;17:1211–1221.
- De Kanter CTMM, Drenth JPH, Arends JE, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53:409–427.
- European Medicines Agency. Olysio: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf
- Food and Drug Administration. Olysio: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2013 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf
- European Medicines Agency. Sovaldi : EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf
- Food and Drug Administration. Sovaldi: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2014 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000ClinPharmR.pdf
- European Medicines Agency. Daklinza: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf
- Food and Drug Administration. Daklinza: Label [Internet]. 2015 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf
- Bifano M, Sevinsky H, Persson A, et al. Single-dose pharmacokinetics of BMS-790052 in subjects with hepatic impairment compared with healthy subjects. In: Hepatology. Malden (MA): Wiley-Blackwell; 2011. p. 1004A.
- Food and Drug Administration. Harvoni: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2014 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000ClinPharmR.pdf
- Food and Drug Administration. Viekira Pak: Clinical Pharmacology Biopharmaceutics Review(s) [Internet]. 2015 [cited 2015 Aug 11]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206619Orig1s000ClinPharmR.pdf
- European Medicines Agency. Viekirax: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf
- European Medicines Agency. Exviera: EPAR - Product Information [Internet]. 2015 [cited 2015 Aug 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf
- European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
- Haché C, Villeneuve J-P. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006;7:1835–1843.
- Zhou X-J, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother. 2006;50:1721–1726.
- Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998;54:363–366.
- Food and Drug Administration. Viread: Label [Internet]. 2015 [cited 2015 Aug 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021356s049,022577s007lbl.pdf
- Schaad HJ, Petty BG, Grasela DM, et al. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrob Agents Chemother. 1997;41:2793–2796.
- Dominguez S, Ghosn J, Peytavin G, et al. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. J Antimicrob Chemother. 2010;65:2445–2449.
- Veronese L, Rautaureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother. 2000;44:821–826.
- Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis. Am J Health Syst Pharm. 2014;71:1621–34.
- Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet. 1976;1:297–308.
- Marshall JP, Salt WB, Elam RO, et al. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. Gastroenterology. 1977;73:1388–1392.
- Ko RJ, Sattler FR, Nichols S, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease. Antimicrob Agents Chemother. 1991;35:1376–1380.
- Hary L, Andrejak M, Leleu S, et al. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol. 1989;36:613–616.
- Stoeckel K, Tuerk H, Trueb V, et al. Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther. 1984;36:500–509.
- Hayton WL, Kneer J, Blouin RA, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis. Antimicrob Agents Chemother. 1990;34:1318–1322.
- Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet. 1993;24:46–58.
- Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother. 1990;26(Suppl B):61–67.
- Granneman GR, Mahr G, Locke C, et al. Pharmacokinetics of temafloxacin in patients with liver impairment. Clin Pharmacokinet. 1992;22(Suppl 1):24–32.
- Chu SY, Granneman GR, Pichotta PJ, et al. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol. 1993;33:480–485.
- Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother. 1993;31(Suppl E):57–63.
- Acocella G, Bonollo L, Garimoldi M, et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972;13:47–53.
- Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–493.
- Lacroix C, Tranvouez JL, Phan Hoang T, et al. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Arzneimittelforschung. 1990;40:76–79.
- Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol. 2011;51:93–101.
- Lau AH, Evans R, Chang CW, et al. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother. 1987;31:1662–1664.
- Loft S, Sonne J, Døssing M, et al. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol. 1987;22:117–123.
- Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–1034.
- Bourget P, Lesne-Hulin A, Ecoffey C, et al. Perioperative pharmacokinetics of piperacillin during liver transplantation. Int J Clin Pharmacol Ther. 1996;34:550–554.
- Zapater P, Lasso De La Vega MC, Horga JF, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther. 2004;20:29–36.
- Imani F, Motavaf M, Safari S, et al. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon. 2014;14:e23539.
- Zapater P, Llanos L, Barquero C, et al. Acute effects of dipyrone on renal function in patients with cirrhosis: A randomized controlled trial. Basic Clin Pharmacol Toxicol. 2015;116:257–263.
- Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41:579–587.
- Hasselström J, Eriksson S, Persson A, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29:289–297.
- Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83–84.
- Tallgren M, Olkkola KT, Seppälä T, et al. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997;61:655–661.
- Amorós A, Aparicio JR, Garmendia M, et al. Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy. Gastrointest Endosc. 2009;70:262–268.
- Weston BR, Chadalawada V, Chalasani N, et al. Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol. 2003;98:2440–2447.
- Meierhenrich R, Gauss A, Mühling B, et al. The effect of propofol and desflurane anaesthesia on human hepatic blood flow: a pilot study. Anaesthesia. 2010;65:1085–1093.
- Mandell MS, Durham J, Kumpe D, et al. The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg. 2003;97:1573–1577.
- Branch RA, James J, Read AE. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol. 1976;3:243–249.
- Department of Health. Australian Government. Australian Public Assessment Report for Terlipressin. [Internet]. 2013 [cited 2015 Dec 07]. Available from: http://www.ikariaaust.com/lucassin-terlipressin.
- Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and harmacodynamic effects. Gut. 1994;35(3 Suppl):S1–4.
- Jenkins SA, Nott DM, Baxter JN. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. HPB Surg. 1998;11(1):13–21.
- Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46:985–996.
- Lucena MI, Andrade RJ, Tognoni G, et al. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59:71–76.
- Food and Drug Administration. Depakene (valproic acid) capsules and oral solution: Label [Internet]. 2015 [cited 2015 Sep 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018081s062,018082s045lbl.pdf
- Brockmöller J, Thomsen T, Wittstock M, et al. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005;77:529–541.
- Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998;34:33–46.